A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (Brightness)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by AbbVie
Sponsor:
Collaborators:
United States Oncology
NSABP Foundation Inc
Grupo Espanol de Investigacion del Cancer de Mama
Austrian Breast & Colorectal Cancer Study Group
Alliance for Clinical Trials in Oncology
German Breast Group
Information provided by (Responsible Party):
AbbVie
ClinicalTrials.gov Identifier:
NCT02032277
First received: December 13, 2013
Last updated: July 11, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2016
  Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)